Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (3) : 559-574     DOI: 10.14336/AD.2019.0612
Orginal Article |
Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome
Zhou Hefeng1, Li Shengnan1, Li Chuwen1, Yang Xuanjun1,2, Li Haitao1, Zhong Hanbing2, Lu Jia-Hong1,*, Lee Simon Ming-Yuen1,*
1State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
2Department of Biology, South University of Science and Technology, Shenzhen, China.
Download: PDF(2036 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Parkinson’s disease (PD), the second most common neurodegenerative disorder, is neuropathologically characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the presence of Lewy bodies in surviving neurons. α-synuclein (α-syn) is the major component of Lewy bodies and its deposition in neurons is critical pathological event in the pathogenesis of PD. Herein, we reported that Oxyphylla A, a novel lead compound from the fruit of Alpinia oxyphylla, significantly promoted α-syn degradation in a cellular PD model. When exploring the molecular pathways, we found that Oxyphylla A promoted α-syn degradation in a ubiquitin proteasome system (UPS)-dependent and autophagy-independent manner. We further confirmed that Oxyphylla A enhanced UPS activity by upregulating 20S subunit PSMB8 expression. A mechanism study revealed that Oxyphylla A activated the PKA/Akt/mTOR pathway to trigger PSMB8 expression and enhance UPS activity. Finally, we illustrated that Oxyphylla A alleviated the accumulation of both Triton-soluble and Triton-insoluble forms of α-syn and protected against α-syn-induced neurotoxicity in A53T α-syn transgenic mice. These findings suggest that the activation of UPS, via small molecular UPS enhancers including Oxyphylla A, may be a therapeutic strategy for intervention against PD and related diseases.

Keywords Parkinson’s disease      α-synuclein      degradation      proteasome      neuroprotection     
Corresponding Authors: Lu Jia-Hong,Lee Simon Ming-Yuen   
About author:

These authors contributed equally to this work.

Just Accepted Date: 21 August 2019   Issue Date: 13 May 2020
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Zhou Hefeng
Li Shengnan
Li Chuwen
Yang Xuanjun
Li Haitao
Zhong Hanbing
Lu Jia-Hong
Lee Simon Ming-Yuen
Cite this article:   
Zhou Hefeng,Li Shengnan,Li Chuwen, et al. Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome[J]. Aging and disease, 2020, 11(3): 559-574.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2019.0612     OR
Figure 1.  Oxyphylla A promotes the degradation of WT and mutant α-syn in cell models. (A) Chemical structure of Oxyphylla A. Inducible PC12/A53T-α-syn cells were treated with different concentrations of Oxyphylla A or 0.1% (v/v) DMSO for 24 h, and then analyzed by MTT assay (B) and LDH assay (C). Inducible PC12/WT-α-syn (D), A30P-α-syn (E) and A53T-α-syn (F) cells were treated with 1 μg/ml Dox for 24 h to induce the expression of WT or mutant α-syn, and then with different concentrations of Oxyphylla A or 0.1% (v/v) DMSO for another 24 h, cells were lysed in RIPA lysis buffer. (G) PC12/A53T-α-syn cells were induced with 1 μg/ml Dox for 24 h, and then treated with Oxyphylla A (100 μM) for different time periods. (H) After treatment with Oxyphylla A (100 μM), cells were lysed in 1% Triton X-100. The Triton-soluble fractions were subjected to Western blotting analysis. (I) Triton-insoluble fractions were also subjected to Western blotting analysis. Representative Western blotting and data analysis of three independent experiments are shown. Data are represented as the mean ± SD. ###P < 0.001 as compared to control group; *P < 0.05, **P < 0.01, ***P < 0.001, as compared to Dox group.
Figure 2.  Oxyphylla A promotes α-syn degradation via the UPS. (A) Inducible PC12/A53T-α-syn cells were treated with or without 1 μg/ml Dox for 24 h, and then with 100 μΜ Oxyphylla A, 30 μΜ CQ, 0.1 μΜ MG132 or 0.1% (v/v) DMSO for another 24 h. (B) Inducible PC12/A53T-α-syn cells were treated with 1 μg/ml Dox for 24 h, and then treated with 100 μΜ Oxyphylla A for different time periods. Representative Western blotting and data analysis of three independent experiments are shown. The proteasomal enzyme activities were measured using specific bioluminogenic enzyme substrates for chymotrypsin-like (C), trypsin-like (D), and caspase-like (E) activity. Data from three independent experiments are represented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3.  Oxyphylla A promotes α-syn degradation through upregulating the expression of genes encoding proteasome subunit beta type-8 (PSMB8). (A) PC12/A53T-α-syn cells were treated with 1 μg/ml Dox for 24 h and then with 100 μΜ Oxyphylla A for another 24 h. The levels of PSMB8 mRNA were determined by qRT-PCR. (B) PC12/A53T-α-syn cells were treated with Oxyphylla A for 24 h and the protein level of PSMB8 was detected by Western blotting analysis. (C) PC12/A53T-α-syn cells were transduced by PSMB8-shRNA or control-shRNA, treated with Dox for 24 h and then treated with 100 μΜ Oxyphylla A for another 24 h. (D) PC12/A53T-α-syn cells were transfected with PSMB8 or empty vector for 24 h and treated with 1 μg/ml Dox for another 24 h. Cell lysates were subjected to Western blotting analysis. Data are represented as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, as compared to control group.
Figure 4.  Oxyphylla A promotes PSMB8 expression and enhances proteasomal activity through the PKA/Akt/mTOR pathway. Inducible PC12/A53T-α-syn cells were treated with 1 μg/ml Dox for 24 h and then with Oxyphylla A (100 μM) for the indicated time periods. The expression ratios of phosphorylated PKA/total PKA (A), phosphorylated Akt/total Akt (B), phosphorylated p-mTOR/total mTOR (C) and phosphorylated p-p70s6k/total p70s6k (D) were detected by Western blotting analysis. PC12/A53T-α-syn cells were pretreated with or without PKA inhibitor H-89 (10 μM) for 1 h and then treated with Oxyphylla A (100 μM) for 30 min. The expression ratios of phosphorylated Akt/total Akt (E), phosphorylated p70S6K/total p70S6K (F) were analyzed by Western blotting. PC12/A53T-α-syn cells were pretreated with or without PKA inhibitor H-89 (10 μM) for 1 h and then treated with Oxyphylla A (100 μM) for another 24 h. The protein levels of PSMB8 were determined by Western blotting (G). Cellular chymotrypsin-like activity was determined by specific bioluminogenic enzyme substrates (H). Representative Western blotting and data analysis of three independent experiments are shown. Data are represented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5.  Oxyphylla A protects mice against α-syn-induced neurotoxicity. (A) Experimental scheme. Ten-month-old WT or homozygous A53T human α-syn Tg mice were gavaged daily with Oxyphylla A (30 mg/kg) or olive oil (0.2 ml) for 4 weeks. (B) In the rotarod test, the time spent on the rotating drum before falling was recorded and analyzed for each mouse (n = 10). (C) Representative images of tyrosine hydroxylase positive (TH+) neurons in the SNc (n = 5). (D) Quantification of TH+ cells in the SNc (n = 5). Data are represented as means ± SD. ##P < 0.01, compared to the WT group; *P < 0.05, compared to Tg group.
Figure 6.  Oxyphylla A promotes the degradation of Triton-soluble and Triton-insoluble α-syn in A53T α-syn Tg mouse brains. Ten-month-old homozygous A53T human α-syn Tg mice were gavaged daily with Oxyphylla A (30 mg/kg) or olive oil (0.2 ml) for 4 weeks. The cortex (A), midbrain (B) and striatum (C) were homogenized and A53T α-syn was analyzed by Western blotting. (D) Whole brain levels of Triton-insoluble α-syn were analyzed by Western blotting and semi-quantified by densitometry. The expression ratios of phosphorylated PKA/total PKA (E), p-Akt/total Akt (F), p-p70S6K/total p70S6K (G) and the levels of PSMB8 (H) in whole brain were detected by Western blotting and semi-quantified by densitometry. Data are represented as means ± SD (n = 5). *P < 0.05, **P < 0.05, ***P < 0.001 compared to control.
Figure 7.  A proposed schematic of Oxyphylla A promotes degradation of α-syn via modulation of PKA/AKt/mTOR/PSMB8 pathway.
[1] Santangelo G, Barone P, Trojano L, Vitale C (2013). Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord, 19:645-653.
[2] Niu H, Shen L, Li T, Ren C, Ding S, Wang L, et al. (2018). Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson's disease. Transl Neurodegener, 7:25.
[3] Deng Y, Jiang B, Rankin CL, Toyo-Oka K, Richter ML, Maupin-Furlow JA, et al. (2018). Methionine sulfoxide reductase A (MsrA) mediates the ubiquitination of 14-3-3 protein isotypes in brain. Free Radic Biol Med, 129:600-607.
[4] Lashuel HA, Overk CR, Oueslati A, Masliah E (2013). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature Rev Neurosci, 14:38-48.
[5] Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, et al. (2004). Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 117:1017-1024.
[6] Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, Buell AK, et al. (2016). Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of alpha-synuclein aggregation. Proc Natl Acad Sci U S A, 113:10328-10333.
[7] Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, et al. (2014). Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging, 35:2180 e2181-2185.
[8] Li J, Uversky VN, Fink AL (2001). Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 40:11604-11613.
[9] Kara E, Kiely AP, Proukakis C, Giffin N, Love S, Hehir J, et al. (2014). A 6.4 Mb duplication of the alpha-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. JAMA Neurol, 71:1162-1171.
[10] Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302:841.
[11] Kim S, Park JM, Moon J, Choi HJ (2014). Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine beta-hydroxylase and is associated with abnormal adaptive responses to immobilization stress. Exp Neurol, 252:63-74.
[12] Migdalska-Richards A, Wegrzynowicz M, Rusconi R, Deangeli G, Di Monte DA, Spillantini MG, et al. (2017). The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain, 140:2706-2721.
[13] Sotiriou E, Vassilatis DK, Vila M, Stefanis L (2010). Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol Aging, 31:2103-2114.
[14] Xu L, Pu J (2016). Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinsons Dis, 2016:1720621.
[15] Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N (2017). Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol Neurodegener, 12:52.
[16] Suresh SN, Chavalmane AK, Dj V, Yarreiphang H, Rai S, Paul A, et al. (2017). A novel autophagy modulator 6-Bio ameliorates SNCA/alpha-synuclein toxicity. Autophagy, 13:1221-1234.
[17] Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VMY (2013). Lewy Body-like alpha-Synuclein Aggregates Resist Degradation and Impair Macroautophagy. J Biol Chem, 288:15194-15210.
[18] Batelli S, Peverelli E, Rodilossi S, Forloni G, Albani D (2011). Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience, 195:128-137.
[19] Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999). Degradation of alpha-synuclein by proteasome. J Biol Chem, 274:33855-33858.
[20] Alvarez-Castelao B, Goethals M, Vandekerckhove J, Castano JG (2014). Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines. Biochim Biophys Acta, 1843:352-365.
[21] Lee HJ, Khoshaghideh F, Patel S, Lee SJ (2004). Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci, 24:1888-1896.
[22] Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003). Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem, 278:25009-25013.
[23] Lindersson E, Beedholm R, Hojrup P, Moos T, Gai WP, Hendil KB, et al. (2004). Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem, 279:12924-12934.
[24] Cook C, Petrucelli L (2009). A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta, 1792:664-675.
[25] Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science, 305:1292-1295.
[26] da Fonseca TL, Villar-Pique A, Outeiro TF (2015). The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules, 5:435-471.
[27] Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L (2008). Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem, 283:23542-23556.
[28] Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan ZY, Rockenstein E, Masliah E, Hyman BT, et al. (2011). Distinct Roles In Vivo for the Ubiquitin-Proteasome System and the Autophagy-Lysosomal Pathway in the Degradation of alpha-Synuclein. J Neurosci, 31:14508-14520.
[29] Yang F, Yang YP, Mao CJ, Liu L, Zheng HF, Hu LF, et al. (2013). Crosstalk between the proteasome system and autophagy in the clearance of alpha-synuclein. Acta Pharmacol Sin, 34:674-680.
[30] Oertel WH (2017). Recent advances in treating Parkinson's disease. F1000Res, 6:260.
[31] Ho YS, So KF, Chang RCC (2011). Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia. Chin Med, 6:15.
[32] Ren ZL, Zuo PP (2012). Neural regeneration: role of traditional Chinese medicine in neurological diseases treatment. J Pharmacol Sci, 120:139-145.
[33] Wang ZY, Liu JY, Yang CB, Malampati S, Huang YY, Li MX, et al. (2017). Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy-Lysosome Pathway: A Systematic Review.? Phytother Res, 31:1119-1127.
[34] Li G, Zhang Z, Quan Q, Jiang R, Szeto SS, Yuan S, et al. (2016). Discovery, Synthesis, and Functional Characterization of a Novel Neuroprotective Natural Product from the Fruit of Alpinia oxyphylla for use in Parkinson's Disease Through LC/MS-Based Multivariate Data Analysis-Guided Fractionation. J Proteome Res, 15:2595-2606.
[35] Zhang ZJ, Cheang LC, Wang MW, Li GH, Chu IK, Lin ZX, et al. (2012). Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol, 32:27-40.
[36] Gan L, Vargas MR, Johnson DA, Johnson JA (2012). Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci, 32:17775-17787.
[37] Yang X, Xu Y, Wang T, Shu D, Guo P, Miskimins K, et al. (2017). Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biol, 11:653-662.
[38] Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002). Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34:521-533.
[39] Tatenhorst L, Tonges L, Saal KA, Koch JC, Szego EM, Bahr M, et al. (2014). Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. J Neuropathol Exp Neurol, 73:770-779.
[40] Brand M, Rampalli S, Chaturvedi CP, Dilworth FJ (2008). Analysis of epigenetic modifications of chromatin at specific gene loci by native chromatin immunoprecipitation of nucleosomes isolated using hydroxyapatite chromatography. Nat Protoc, 3:398-409.
[41] Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol, 172:3461-3471.
[42] Lokireddy S, Kukushkin NV, Goldberg AL (2015). cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci U S A, 112:E7176-7185.
[43] Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, et al. (2016). Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med, 22:46-53.
[44] Zondler L, Kostka M, Garidel P, Heinzelmann U, Hengerer B, Mayer B, et al. (2017). Proteasome impairment by alpha-synuclein. PLoS One, 12:e0184040.
[45] Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. (2011). Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci, 31:14508-14520.
[46] Lin JT, Chang WC, Chen HM, Lai HL, Chen CY, Tao MH, et al. (2013). Regulation of Feedback between Protein Kinase A and the Proteasome System Worsens Huntington's Disease. Mol Cell Biol, 33:1073-1084.
[47] Sha Z, Peth A, Goldberg AL (2011). Keeping proteasomes under control-a role for phosphorylation in the nucleus. Proc Natl Acad Sci USA, 108:18573-18574.
[48] Noguchi M, Hirata N, Suizu F (2014). The links between AKT and two intracellular proteolytic cascades: Ubiquitination and autophagy. BBA-Rev Cancer, 1846:342-352.
[49] Yun YS, Kim KH, Tschida B, Sachs Z, Noble-Orcutt KE, Moriarity BS, et al. (2016). mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell, 61:625-639.
[50] Zhang YN, Nicholatos J, Dreier JR, Ricoult SJH, Widenmaier SB, Hotamisligil GS, et al. (2014). Coordinated regulation of protein synthesis and degradation by mTORC1. Nature, 513:440-443.
[51] Ellis JM, Fell MJ (2017). Current approaches to the treatment of Parkinson's Disease. Bioorganic Med Chem Lett, 27:4247-4255.
[1] Supplementary data Download
[1] Beheshti Iman, Mishra Shiwangi, Sone Daichi, Khanna Pritee, Matsuda Hiroshi. T1-weighted MRI-driven Brain Age Estimation in Alzheimer’s Disease and Parkinson’s Disease[J]. Aging and disease, 2020, 11(3): 618-628.
[2] Seong Gak Jeon, Anji Yoo, Dong Wook Chun, Sang Bum Hong, Hyunju Chung, Jin-il Kim, Minho Moon. The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer’s Disease-related Pathogenesis[J]. Aging and disease, 2020, 11(3): 705-724.
[3] Le Wang, Yang Liu, Shuxin Yan, Tianshu Du, Xia Fu, Xiaoli Gong, Xinyu Zhou, Ting Zhang, Xiaomin Wang. Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson’s Disease[J]. Aging and disease, 2020, 11(2): 254-268.
[4] Yuan Tan, Minjing Ke, Zhijian Huang, Cheong-Meng Chong, Xiaotong Cen, Jia-Hong Lu, Xiaoli Yao, Dajiang Qin, Huanxing Su. Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived IPSCs-Based Modeling of Late-Onset Parkinson’s Disease[J]. Aging and disease, 2019, 10(5): 1037-1048.
[5] Ya-Fan Zhou, Jing Wang, Man-Fei Deng, Bin Chi, Na Wei, Jian-Guo Chen, Dan Liu, Xiaoping Yin, Youming Lu, Ling-Qiang Zhu. The Peptide-Directed Lysosomal Degradation of CDK5 Exerts Therapeutic Effects against Stroke[J]. Aging and disease, 2019, 10(5): 1140-1145.
[6] Elizabeth Qian, Yue Huang. Subtyping of Parkinson’s Disease - Where Are We Up To?[J]. Aging and disease, 2019, 10(5): 1130-1139.
[7] Xu-Xu Deng, Shan-Shan Li, Feng-Yan Sun. Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling[J]. Aging and disease, 2019, 10(4): 807-817.
[8] Jinghui Xu, Xiaodi Fu, Mengqiu Pan, Xiao Zhou, Zhaoyu Chen, Dongmei Wang, Xiaomei Zhang, Qiong Chen, Yanhui Li, Xiaoxian Huang, Guanghui Liu, Jianjun Lu, Yan Liu, Yafang Hu, Suyue Pan, Qing Wang, Qun Wang, Yunqi Xu. Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients[J]. Aging and disease, 2019, 10(3): 601-610.
[9] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[10] Fan Liu, Jianfei Lu, Anatol Manaenko, Junjia Tang, Qin Hu. Mitochondria in Ischemic Stroke: New Insight and Implications[J]. Aging and disease, 2018, 9(5): 924-937.
[11] De Lazzari Federica, Bubacco Luigi, Whitworth Alexander J, Bisaglia Marco. Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 716-728.
[12] Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 590-604.
[13] Morroni Fabiana, Sita Giulia, Graziosi Agnese, Turrini Eleonora, Fimognari Carmela, Tarozzi Andrea, Hrelia Patrizia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. Aging and disease, 2018, 9(4): 605-622.
[14] Yan Tao, Venkat Poornima, Chopp Michael, Zacharek Alex, Yu Peng, Ning Ruizhuo, Qiao Xiaoxi, Kelley Mark R., Chen Jieli. APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats[J]. Aging and disease, 2018, 9(3): 453-466.
[15] Zhang Zheng, Zhang Linlei, Ding Yuchuan, Han Zhao, Ji Xunming. Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence[J]. Aging and disease, 2018, 9(3): 507-522.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd